Feed REGN
RE

Regeneron Pharmaceuticals

REGN · NASDAQ

$774.11 -1.83% (-$14.42)
1M -3.95%
Market Cap $79.8B
P/E Ratio 18.42x
Div. Yield 0.48%
ROE 13.81%

Bulios Fair Price

$853.63

10.3% upside

Trenutna cena

$774.11

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica REGN trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Strong
7/9
Valuation
52 /100
Fair
P/FCF 22.64x
P/E 18.42x
P/B 2.51x
Growth
40 /100
Stable
FCF growth 2.66%
EPS growth 2.77%
Book val. growth 11.31%
Profitability
100 /100
Strong
Op. margin 25.56%
Gross margin 84.86%
FCF margin 22.67%
Quality
58 /100
Average
ROA 10.37%
ROIC 9.19%
Asset turnover 0.37x
Debt
100 /100
Low
Int. coverage 94.25x
Debt/Equity 0.06x
Net debt/EBITDA -0.08x
Stability
77 /100
Stable
EPS volatility 10.59%
Beta 0.24x
Profitable years 6

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o REGN
Online

O podjetju

Regeneron Pharmaceuticals (REGN) is an American biotechnology company specializing in the development and production of drugs for the treatment of serious diseases. With a broad portfolio of medicinal products, such as Eylea and Dupixent, Regeneron Pharmaceuticals is one of the leading players in the biotechnology sector. The company is known for its emphasis on scientific research and innovation, allowing it to bring groundbreaking treatments to market. Regeneron Pharmaceuticals is also involved in partnerships with other pharmaceutical companies and academic institutions to expand its research and development capabilities. Regeneron Pharmaceuticals (REGN) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on innovation and scientific research.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Leonard S. Schleifer

Employees

15,410

Headquarters

Tarrytown

Prihajajoči dogodki

28 OKT.

Earnings

Upcoming earnings report

42d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.